Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone650-574-3000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$22.13 billion
Profitability
Miscellaneous
Employees11,000
Next Earnings Date10/24/2019 (Confirmed)
OptionableOptionable
Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions
What is Gilead Sciences' stock symbol?
Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."
How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?
Gilead Sciences announced a quarterly dividend on Tuesday, July 30th. Stockholders of record on Friday, September 13th will be given a dividend of $0.63 per share on Friday, September 27th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.90%. The ex-dividend date is Thursday, September 12th. View Gilead Sciences' Dividend History.
How were Gilead Sciences' earnings last quarter?
Gilead Sciences, Inc. (NASDAQ:GILD) posted its earnings results on Tuesday, July, 30th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.68 by $0.14. The biopharmaceutical company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.54 billion. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. The business's revenue was down 2.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.91 EPS. View Gilead Sciences' Earnings History.
When is Gilead Sciences' next earnings date?
How can I listen to Gilead Sciences' earnings call?
Gilead Sciences will be holding an earnings conference call on Thursday, October 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Gilead Sciences issued on next quarter's earnings?
Gilead Sciences updated its FY 2019 earnings guidance on Tuesday, July, 30th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $21.6-22.1 billion, compared to the consensus revenue estimate of $22.06 billion.
What price target have analysts set for GILD?
23 Wall Street analysts have issued 12 month price objectives for Gilead Sciences' shares. Their predictions range from $60.00 to $95.00. On average, they expect Gilead Sciences' share price to reach $82.90 in the next year. This suggests a possible upside of 28.3% from the stock's current price. View Analyst Price Targets for Gilead Sciences.
What is the consensus analysts' recommendation for Gilead Sciences?
23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 1 sell rating, 4 hold ratings, 17 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gilead Sciences.
What are Wall Street analysts saying about Gilead Sciences stock?
Here are some recent quotes from research analysts about Gilead Sciences stock:
- 1. Needham & Company LLC analysts commented, "Gilead reported $5.28B in 1Q19 total revenue, in line w/ our $5.27B and consensus $5.3B ests. Product sales were $5.20B (-8% q/q), matching our $5.16B and consensus $5.2B ests. Mgmt had guided for 12-14% sequential decline. All annual guidance unch. Non-GAAP EPS $1.76 was above our $1.64 and consensus $1.61 ests. New CEO O’Day outlined priorities (Strengthen pipeline [internal and external business development]; Ensure optimal commercial delivery; and Reassess organizational structure [‘evolution not revolution’]) and announced that Kite will operate as a separate business unit w/ a new CEO reporting directly to O’Day. Filgotinib MAA to be submitted 3Q19, but no update yet on strategy/ timing for NDA submission. NASH ATLAS drug combination trial results expected 4Q19 (unch). HOLD." (5/6/2019)
- 2. Cowen Inc analysts commented, "NTLA reported 1Q results of $10.4M in collaboration revenue, $34M in -$0.49 vs consensus EPS of -$0.57. 1Q cash balance was $296.6M, which management estimates will fund operations into 1H 2021. The call included several updates on the pipeline in in-vivo editing and ex-vivo engineered T-Cells: 1) NTLA remains on track for NDA submission of NTLA-2001 for ATTR in 2020 and preparations (manufacturing & toxicology) are ongoing. 2) Data presented at ASGCT was the first demonstration of CRISPR/Cas9-based targeted insertion in the liver of non-human primates. We view this as a validation of NTLA’s modular LNP+AAV approach to in-vivo editing. 3) ASGCT presentation on engineered cell therapy (WT1 insertion into >95% of isolated T-cells) shows progress in cell therapy." (5/3/2019)
- 3. According to Zacks Investment Research, "Gilead’s HIV franchise maintains momentum, driven by continued uptake of Genvoya and Odefsey, and the rapid adoption of Biktarvy. However, the company’s HCV franchise continues to witness a slowdown across key markets, including the United States and Europe, as a result of competition and pricing pressure. Consequently, Gilead shifted focus to its HIV franchise, and newer avenues like CAR-T therapy and NASH. However, the company suffered a setback with the failure of a late-stage study on selonsertib in patients with compensated cirrhosis (F4) due to NASH. Shares have underperformed the industry in the past three months." (5/2/2019)
- 4. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $87 Price Target. We do not think today’s announcement that GILD’s STELLAR3 study was unsuccessful will be met with much surprise after the previous STELLAR4 failure: no changes to our estimates. The fibrosis improvement was least for the high dose and greatest for the placebo with a p-value at the higher dose of 0.42 and at lower dose it was 0.93. After both STELLAR Ph3 readouts we are focused on how Gilead will advance its strategy in NASH; we think M&A could be a strategy." (4/25/2019)
- 5. Mizuho analysts commented, "DERM is a leading dermatology company with commercial and pipeline advancements that could drive upwards earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $25." (4/22/2019)
Has Gilead Sciences been receiving favorable news coverage?
News articles about GILD stock have been trending negative recently, according to InfoTrie. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Gilead Sciences earned a news impact score of -2.8 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Gilead Sciences.
Are investors shorting Gilead Sciences?
Gilead Sciences saw a drop in short interest during the month of September. As of September 30th, there was short interest totalling 13,910,000 shares, a drop of 5.1% from the August 30th total of 14,660,000 shares. Based on an average daily volume of 5,960,000 shares, the short-interest ratio is presently 2.3 days. Currently, 1.1% of the company's stock are sold short. View Gilead Sciences' Current Options Chain.
Who are some of Gilead Sciences' key competitors?
Some companies that are related to Gilead Sciences include Amgen (AMGN), Biogen (BIIB), Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Qiagen (QGEN), bluebird bio (BLUE), Moderna (MRNA), China Biologic Products (CBPO), argenx (ARGX), Repligen (RGEN), Ablynx (ABLYF), Spark Therapeutics (ONCE) and Adaptive Biotechnologies (ADPT).
What other stocks do shareholders of Gilead Sciences own?
Who are Gilead Sciences' key executives?
Gilead Sciences' management team includes the folowing people:
- Ms. Robin L. Washington, CFO & Exec. VP (Age 56)
- Dr. John G. McHutchison M.D., FRACP, Chief Scientific Officer and Head of R&D (Age 61)
- Mr. Gregg H. Alton, Chief Patient Officer (Age 53)
- Ms. Laura Hamill, Exec. VP of Worldwide Commercial Operations (Age 54)
- Mr. Daniel O'Day, Chairman & CEO (Age 55)
Who are Gilead Sciences' major shareholders?
Gilead Sciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Manning & Napier Group LLC (0.03%), Meyer Handelman Co. (0.03%), Gulf International Bank UK Ltd (0.02%), Pacer Advisors Inc. (0.02%), Gofen & Glossberg LLC IL (0.02%) and Nexus Investment Management Inc. (0.02%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, Olsen Per Wold, Richard James Whitley and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.
Which institutional investors are selling Gilead Sciences stock?
GILD stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Decatur Capital Management Inc., Lawson Kroeker Investment Management Inc. NE, Stonebridge Capital Management Inc., American National Bank, KG&L Capital Management LLC, Crossmark Global Holdings Inc. and Welch & Forbes LLC. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Gayle E Wilson, John C Martin, John Francis Cogan, Olsen Per Wold and Richard James Whitley. View Insider Buying and Selling for Gilead Sciences.
Which institutional investors are buying Gilead Sciences stock?
GILD stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Fulton Bank N.A., Verity & Verity LLC, Pacer Advisors Inc., Meyer Handelman Co., Clarus Wealth Advisors, Gradient Investments LLC and First Hawaiian Bank. View Insider Buying and Selling for Gilead Sciences.
How do I buy shares of Gilead Sciences?
Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Gilead Sciences' stock price today?
One share of GILD stock can currently be purchased for approximately $64.61.
How big of a company is Gilead Sciences?
Gilead Sciences has a market capitalization of $81.83 billion and generates $22.13 billion in revenue each year. The biopharmaceutical company earns $5.46 billion in net income (profit) each year or $6.15 on an earnings per share basis. Gilead Sciences employs 11,000 workers across the globe.View Additional Information About Gilead Sciences.
What is Gilead Sciences' official website?
How can I contact Gilead Sciences?
Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]
MarketBeat Community Rating for Gilead Sciences (NASDAQ GILD)
MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe GILD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GILD will underperform the S&P 500 over the long term. You may vote once every thirty days.
